Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
At present, cartilage implants created using stem cells can only be constructed as a solid shape, acting as an interim measure before the almost inevitable need for total joint replacement.
Minute whiskers of nanoscale dimensions taken from sea creatures could hold the key to creating working human muscle tissue, University of Manchester researchers have discovered.
In a scientific breakthrough, five boys who were unable to urinate due to pelvic injury were cured for up to six years after getting new lab-grown urethras or urinary tubes that connect with the bladder. This breakthrough comes from Wake Forest University researcher Anthony Atala. It was in 2006 that the team reported the first successful implantation of lab-grown urinary bladders into humans. Today six years after the operation all of the boys continue to do well, with normal or near-normal urinary flow. The boy first treated is now 16 years old and received his lab-grown urethra over six years ago.
Researchers at the Institute for Regenerative Medicine at Wake Forest University Baptist Medical Center and colleagues reported today on a new advance in tissue engineering.
Biologists tend to look at cells in bulk, observing them as a group and taking the average behavior as the norm - the assumption is that genetically identical cells all behave the same way.
Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.
In what seems like science fiction, Dr. Anthony Atala, a regenerative medicine specialist at Wake Forest University, is pioneering the use of printing techniques to reconstruct and repair human flesh and organs. His basis is a combination of cultured human cells and scaffolding built or woven from organic material.
Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, and Hadasit Medical Research Services & Development Ltd., the technology transfer company of the Hadassah University Medical Center, today announced that they have licensed innovative regenerative membrane implant technology to RegeneCure, which will further develop and commercialize the technology for bone tissue engineering for applications in trauma, spine, and reconstructive cranial and facial orthopedics.
A new review published in WIREs Nanomedicine and Nanobiotechnology explores how nanotechnology may provide powerful new tools that could have a marked impact on the therapeutic and diagnostic measures available to surgeons.
A new review published in WIREs Nanomedicine and Nanobiotechnology explores how nanotechnology may provide powerful new tools that could have a marked impact on the therapeutic and diagnostic measures available to surgeons.
Soon artificial blood vessels could be available ‘off the shelf’. This would mean that heart bypass patients would not have to be subjected to a minor operation to graft veins from other parts of their body. This would also make life easier for surgeons as well.
Texas Children's Hospital in Houston announces that a researcher in its Pediatric Cardiac Bioengineering Laboratory has earned a National Science Foundation Early Career Development Award for his work in studying the causes of congenital heart disease, heart defects, and the development of tissue engineering therapies using stem cells derived from human amniotic fluid.
Transplanting autologous renal progenitor cells, into rat models with kidney damage from pyelonephritis - a type of urinary infection that has reached the kidney - has been found to improve kidney structure and function.
bioMD Limited (ASX: BOD), a company with assets in regenerative tissue engineering technologies today announced that it has made an offer to buy all of the shares in Allied Medical Limited (Allied), a public unlisted company that specialises in the sales, distribution and commercialisation of medical technologies.
BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.
Harvard Bioscience, Inc., a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research and regenerative medicine, is pleased to announce that its novel bioreactor technology was featured on the National Geographic Channel's Explorer television program on February 7, 2011.
The University of South Florida received $5.45 million in grants from the Bill & Melinda Gates Foundation. The first grant is to create advanced devices that mimic the human liver to better study the life cycle of the malaria parasite - particularly the elusive liver stage where the disease may be most vulnerable to attack.
Tufts University today announced the public launch of the Tufts Institute for Biomedical Partnerships website/HUB: www.tuftspharmapartners.org.
Scientists from USA have developed a method to produce a ready made supply of blood vessels for use in heart bypass surgery. A study on baboons and dogs reported in journal Science Translational Medicine suggests vessels could be stored for up to a year and used by any patient. These vessels have been grown earlier from a patient’s own cells, but this takes several months.
Arteriocyte, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.